Edgar Filing: COMPLETE GENOMICS INC - Form 4

COMPLETE GENOMICS INC

Form 4

March 18, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

OMB APPROVAL

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, may continue.

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

\$0.001

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person * OVP VENTURE PARTNERS VI LP			2. Issuer Name and Ticker or Trading Symbol COMPLETE GENOMICS INC [GNOM]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	/O OVP VENTURE 03/14 ARTNERS, 1010 MARKET			3. Date of Earliest Transaction (Month/Day/Year) 03/14/2013				DirectorX 10% Owner Officer (give title below) Other (specify below)			
KIRKLAN	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				<i>A</i>	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative Se	curitie		ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			vate, if Transactiomr Disposed of (D) Code (Instr. 3, 4 and 5) /Year) (Instr. 8) (A) or				Securities Ownership Indirect Beneficially Form: Beneficia Owned Direct (D) Ownershi Following or Indirect (Instr. 4) Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)			
Common Stock, par value \$0.001	03/14/2013			Code V U	Amount 1,424,629 (1)	(D)	Price \$ 3.15	0	D		
Common Stock, par value								0	I	See Footnote	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(2)

Edgar Filing: COMPLETE GENOMICS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to purchase Common Stock	\$ 1.5 <u>(3)</u>	03/18/2013		D	2,282	<u>(3)</u>	(3)	Common Stock	2,282
Warrant to purchase Common Stock	\$ 1.5 <u>(3)</u>	03/18/2013		D	135,939	(3)	(3)	Common Stock	135,939
Warrant to purchase Common Stock	\$ 1.5 <u>(4)</u>	03/18/2013		D	885	<u>(4)</u>	<u>(4)</u>	Common Stockj	885 \$
Warrant to purchase Common Stock	\$ 1.5 <u>(4)</u>	03/18/2013		D	52,735	<u>(4)</u>	<u>(4)</u>	Common Stock	52,735

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting of their runner, runners	Director	10% Owner	Officer	Other		
OVP VENTURE PARTNERS VI LP						
C/O OVP VENTURE PARTNERS		X				
1010 MARKET STREET		Λ				
KIRKLAND, WA 98033						

Reporting Owners 2

Edgar Filing: COMPLETE GENOMICS INC - Form 4

Signatures

/s/ Maureen Monahan, Attorney in Fact for OVP Venture PartnersVI, L.P.

03/18/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - These shares were tendered to Beta Acquisition Corporation (the "Purchaser"), a wholly-owned subsidiary of BGI-Shenzhen, pursuant to Purchaser's offer to purchase all of the outstanding shares of the Issuer at a price of \$3.15 per share (the "Per Share Merger Consideration"), without interest, subject to the terms described in the Offer to Purchase for Cash filed with the Securities and Exchange
- (1) Commission on September 25, 2012 and in the related Letter of Transmittal, together with any amendments or supplements thereto, and the Agreement and Plan of Merger, dated as of September 15, 2012 (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, on March 18, 2013, the Issuer completed its merger (the "Merger") with BGI-Shenzhen, whereby the Issuer became a wholly owned subsidiary of BGI-Shenzhen.
- No shares are owned by OVP Venture Partners VI LP or OVP VI Entrepreneurs Fund, L.P. ("OVP VI Entrepreneurs") following the

 Merger. OVMC VI LLC serves as the general partner of OVP VI Entrepreneurs. Charles P. Waite, Jr. is a managing member of OVMC VI LLC and shares voting and investment power over the shares held by OVP VI Entrepreneurs. Mr. Waite disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
- In accordance with the terms of the Merger Agreement, each warrant exercisable for shares of Issuer common stock that was outstanding immediately prior to the consummation of the Merger was canceled in exchange for the right to receive an amount in cash equal to \$2.82 per warrant, calculated in accordance with the Black-Scholes option pricing formula set forth in the stock purchase warrant agreement.
- In accordance with the terms of the Merger Agreement, each warrant exercisable for shares of Issuer common stock that was outstanding (4) immediately prior to the consummation of the Merger was canceled in exchange for the right to receive an amount in cash equal to \$2.85 per warrant, calculated in accordance with the Black-Scholes option pricing formula set forth in the stock purchase warrant agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3